We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

65 hedge funds and large institutions have $40.1M invested in Palvella Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more call options, than puts

Call options by funds: $126K | Put options by funds: $18K

0.04% less ownership

Funds ownership: 0.63% → 0.59% (-0.04%)

4% less funds holding

Funds holding: 68 → 65 (-3)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

38% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 21

41% less capital invested

Capital invested by funds: $68.3M → $40.1M (-$28.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
65
Holders Change
-3
Holders Change %
-4.41%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
5
Increased
13
Reduced
21
Closed
7
Calls
$126K
Puts
$18K
Net Calls
+$108K
Net Calls Change
-$90K

Top Buyers

1
ACM
Aquilo Capital Management
California
+$483K
2
LCM
Lynx1 Capital Management
Puerto Rico
+$470K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$385K
4
Renaissance Technologies
Renaissance Technologies
New York
+$243K
5
PIM
Platinum Investment Management
Australia
+$196K

Top Sellers

1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.93M
2
GPP
Great Point Partners
Connecticut
-$882K
3
Citigroup
Citigroup
New York
-$556K
4
XT
XTX Topco
Cayman Islands
-$186K
5
Millennium Management
Millennium Management
New York
-$185K
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
51
Prudential Financial
New Jersey
$13K – – –
CHAM
52
Clear Harbor Asset Management
Connecticut
$13K +$17.8K +138 New
OC
53
Oppenheimer & Co
New York
$12K – – –
US Bancorp
54
US Bancorp
Minnesota
$12K – – –
UBS Group
55
UBS Group
Switzerland
$8K +$9.03K +70 +538%
Wells Fargo
56
Wells Fargo
California
$7K – – –
CG
57
Cutler Group
California
$5K – – –
JP Morgan Chase
58
JP Morgan Chase
New York
$3K -$6.96K -54 -60%
Osaic Holdings
59
Osaic Holdings
Arizona
$3K – – –
TC
60
Truvestments Capital
Florida
$2K -$387 -3 -11%
TVWM
61
Tower View Wealth Management
Wisconsin
$1K – – –
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
– -$2.6K -9,869 Closed
XT
63
XTX Topco
Cayman Islands
– -$186K -1,244 Closed
Susquehanna International Group
64
Susquehanna International Group
Pennsylvania
– -$54.3K -421 Closed
Rafferty Asset Management
65
Rafferty Asset Management
New York
– -$55K -370 Closed
CSS
66
Cubist Systematic Strategies
Connecticut
– -$33K -218 Closed
WJWM
67
Williams Jones Wealth Management
New York
– -$29K -197 Closed
Simplex Trading
68
Simplex Trading
Illinois
– -$9.8K -76 -93%
CAPTRUST Financial Advisors
69
CAPTRUST Financial Advisors
North Carolina
– -$2K -13 Closed
Royal Bank of Canada
70
Royal Bank of Canada
Ontario, Canada
– +$258 +2 +200%
1 2
3

PVLA Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2022, worth a combined $40.1M — down 41% from $68.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of PVLA and 5 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.

The largest buyer was Aquilo Capital Management, adding an estimated $483K. The largest seller was Assenagon Asset Management, cutting an estimated $1.93M.

  • 65 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2022, down from 68 in Q2 2022.
  • Funds reported $40.1M of Palvella Therapeutics stock for Q3 2022, down 41% quarter-over-quarter.
  • 5 funds opened new Palvella Therapeutics positions in Q3 2022 and 7 closed out, a net change of -2 holders.
  • The largest Palvella Therapeutics buyer in Q3 2022 was Aquilo Capital Management, an estimated $483K added.
  • The largest Palvella Therapeutics seller in Q3 2022 was Assenagon Asset Management, an estimated $1.93M sold.

Based on aggregated 13F filings for Q3 2022.